61
Ovarian tumor

Ovarian Tumour

Embed Size (px)

Citation preview

Page 1: Ovarian Tumour

Ovarian tumor

Page 2: Ovarian Tumour

Ovarian tumor is one of the most common tumors of the female generative system. Little progress has been made in identifying precursory or in situ stages of these lesions. The 5-year survival rate for all stages is still 35-38%—little better than 35 years ago.

Page 3: Ovarian Tumour

Table 1 Histology of ovarian tumors (WHO, 1972)

1.1. Epithelial ovarian tumorsEpithelial ovarian tumors(1) Serous(1) Serous(2) Mucinous(2) Mucinous(3) Endometrioid(3) Endometrioid(4) Clear cell(4) Clear cell(5) Brenner(5) Brenner(6) Mixed epithelial(6) Mixed epithelial(7) Undifferentiated(7) Undifferentiated

2.2. Gonadal sex cord stromal tumor Gonadal sex cord stromal tumor (1) Granulosa stromal cell tumor(1) Granulosa stromal cell tumor Granulosa cell tumor Granulosa cell tumor Thecoma-fibroma tumor Thecoma-fibroma tumor (a) Theca cell tumor (b) Fibroma (a) Theca cell tumor (b) Fibroma(2) Sertoli leydig cell tumor (androblasto(2) Sertoli leydig cell tumor (androblastoma)ma)(3) Gynandroblastoma(3) Gynandroblastoma

3.3. Lipid (lipoid) cell tumorLipid (lipoid) cell tumor4.4. Ovarian germ cell tumorsOvarian germ cell tumors

(1) Dysgerminoma(1) Dysgerminoma(2) Endodermal sinus tumor (yolk-sac tum(2) Endodermal sinus tumor (yolk-sac tumor)or)

(3) Embryonal carcinoma(3) Embryonal carcinoma(4) Polyembryoma(4) Polyembryoma(5) Choriocarcinoma(5) Choriocarcinoma(6) Teratoma(6) Teratoma Immature Immature Mature Mature(a) Solid (b) Cystic Monoder(a) Solid (b) Cystic Monodermal and highly specialized:mal and highly specialized:(a) Struma ovarii (b) Carcinoid (a) Struma ovarii (b) Carcinoid (c) Others (c) Others(7) Mixed germ cell tumors(7) Mixed germ cell tumors

5.5. GonadoblastomaGonadoblastoma6.6. Non-ovarian specific soft tissue tNon-ovarian specific soft tissue t

umor (sarcoma, fibrosarcoma, lyumor (sarcoma, fibrosarcoma, lymphosarcoma)mphosarcoma)

7.7. Unclassified tumorUnclassified tumor8.8. Metastatic tumorMetastatic tumor9.9. Tumor like condition Follicle cyTumor like condition Follicle cy

sts, lutein cysts, and ssts, lutein cysts, and so ono on

 

Page 4: Ovarian Tumour

Epethelial tumors account for more than 50~70% of all primary ovarian neoplasia and more than 85%-90% of ovarian malignant tumors.

Ovarian germ cell tumors account for 20%-40% of ovarian tumors. They include dysgerminoma, embryonal carcinoma, teratoma, endodermal sinus tumour, choriocarcinoma , and so on.

Page 5: Ovarian Tumour

Sex cord stromal tumors account for about 5% of all ovarian tumors. These tumors are potentially functional, that is, producing hormones, so we call them ovarian functional tumors.

Metastatic tumors account for 5%-10% of ovarian tumors. The primary sites are commonly gastrointestinal tract, breast, genital organs.

Page 6: Ovarian Tumour

High risk factors1. The factors of heredity and family2. Environmental factors 3. Endocrine factors

Page 7: Ovarian Tumour

【 Pathophysiology】 1. Epithelial tumors●Epithelial ovarian tumors present at an averag

e age of 30-60 years.●Cellular proliferation, atypia, and the presence

of stromal invasion are the histologic criteria used to classify malignant potential.

Page 8: Ovarian Tumour

SEROUS CYSTADENOMA

BENIGN TUMORs●comprises approximately 25% of benign ovaria

n neoplasms. ● divided 2 categories, simple and papillary.● Psammoma bodies (small irregular calcificatio

ns) are characteristic of serous tumors.

Page 9: Ovarian Tumour

BORDERLINE SEROUS CYSTADENOMA

papillary formationgood differentiationlack of stromal invasion

Page 10: Ovarian Tumour

SEROUS CYSTADENOCARCINOMA

external papillary excrescences covered by stratified epithelium (usually over 4-5 layers)

nuclear atypia occasional mitotic figures and stromal invi

sion

Page 11: Ovarian Tumour

MUCINOUS CYSTADENOMA

BENIGN TUMORs● Account for approximately 20% of benign ovarian n

eoplasms● Generally unilateral, rounded or ovoid, smooth, gray

ish-white● Cut section reveals the multilocular cysts strikingly fi

lled with a viscous and tremellose mucin. ● The rate of malignant alteration is 5%-10%.

Page 12: Ovarian Tumour

BORDERLINE MUCINOUS CYSTADENOMA

The tumor generally is rather large. Microscopically, cellular stratification occurs. No stromal invasionCellular atypia may be mild to moderate and

a moderate number of mitoses may be present.

Page 13: Ovarian Tumour

MYXOMA PERITONEI

the progressive accumulation of mucin witnin the abdomen

arise from either a mucinous ovarian tumor or from a mucocele of the appendix

account for approximately 2%-5% of mucinous cystadenomas

tumor cells secrete mucin rare cellular atypier and mitotic activity

Page 14: Ovarian Tumour

MUCINOUS CYSTADENOCARCINOMAS

account for 10% of ovarian malignant neoplasms.

Cut section reveals the multilocular cysts filled with a turbid or bloody mucin.

Microscopically, glands are crowded and stroma are rather few. Stromal invasion and cellular atypia may occur strikingly.

In contrast to serous cystadenocarcinoma, this tumor has a more favorable prognosis.

Page 15: Ovarian Tumour

OVARIAN ENDOMETRIOID TUMOR

The malignant kinds of these neoplasms are endometrioid carcinomas, account for 10%-24% of primary ovarian malignant neoplasms.

The histologic type are adenocarcinoma or adenoacanthoma, as in uterine carcinomas.

Endometrial cancer found in the uterus and ovary commonly represents multifocal and not metastatic disease.

Page 16: Ovarian Tumour

OVARIAN GERM CELL TUMOR

They are found in the gonad or at any site from which the germ cell arises or to which it migrates.

This tumor occurs principally in young females─60%-90% in prepuberal and only 4% in postmenopausal women.

Germ cell tumors may contain germ cells as the predominant component.

Page 17: Ovarian Tumour

TERATOMA

Teratoma is one of the most fascinating of all neoplasms.

This tumor may contain tissues of ectoderm, endoderm, and mesoderm.

Page 18: Ovarian Tumour

MATURE TERATOMA

Mature teratoma is the most common tumor of ovary.

This tumor often occurs in patients 20-40 years old. Cut section reveals the unilocular cysts strikingly fi

lled with adipose and hair, sometimes with bone and teeth.

Page 19: Ovarian Tumour

Special varieties of teratoma may produce unusual symptoms.

Malignant change in a primarily benign cystic teratoma is uncommon.

Any tissues may occur malignant change to form every kind of malignant tumors.

The epithelium of scolex easily occur malignant change.

Page 20: Ovarian Tumour

IMMATURE TERATOMA

The tumor commonly occurs during the early reproductive years.

The degree of malignance is bases on the proportion of immature tissues, the cellular differentiation, and the neuroepithelium content.

Maturation at a secondary site has even occurred in some instances.

Page 21: Ovarian Tumour

DYSGERMINOMA

Occurs principally in young females. Comprises approxmately 5% of all malignant ovar

ian neoplasms. Radiation therapy is very effective in this tumor. The 5-year survival rate is 90%.

Page 22: Ovarian Tumour

ENDODERMAL SINUS TUMOR

Occurs principally in young female. The biologic marker is alpha-fetoprotein

(AFP). The survival time has been prolonged by c

ombination chemotherapy and surgery.

Page 23: Ovarian Tumour

OVARIAN GONADAL SEX CORD STROMAL TUMOR

Page 24: Ovarian Tumour

GRANULOSA STROMAL CELL TUMOR

GRANULOSA CELL TUMOR: Found in all age groups and associated with pseud

oprecocious puberty. Early breast development , menstrual disorder, po

stmenopausal vaginal bleeding make up the characteristic symptom.

Page 25: Ovarian Tumour

Laboratory studies demonstrate an increase in the numbers of mature epithelial cells in the vaginal cytologic specimen, elevated urinary and serum estrogen levels, and variant degrees of endometrial proliferation.

The characteristic cell is the round or slightly ovoid granulosa cell with its dark nucleus.

Mitoses are common, and the “ovumlike” Call-Exner bodies are classic.

Page 26: Ovarian Tumour

THECA CELL TUMOR

This tumor offen exists with granulosa cell tumor. The classic cell is short spindle, with abundant cyto

plasm. The endometrium offen becomes proliferative, and

postmenopausal vaginal bleeding may occur. The prognosis is better than that of other ovarian c

arcinomas.

Page 27: Ovarian Tumour

FIBROMA

These tumors account for about 2%-5% of all ovarian tumors.

These solid ovarian tumors may be associated with Meigs’ syndrome.

Page 28: Ovarian Tumour

SERTOLI LEYDIG CELL TUMORS

also be called androblastoma often affect females beneath the ages of 40 years usually be luteinized, simulating the classic pattern

of the testes and producing steroids generally benign, may produce the masculinization The 5-year survival rate is 70%-90%.

Page 29: Ovarian Tumour

OVARIAN METASTATIC TUMORS

Krukenbergs tumor

Page 30: Ovarian Tumour

PATTERNS OF SPREAD

At the time of diagnosis, over 70% of patients with epithelial carcinomas have metastased outside the pelvis.

Page 31: Ovarian Tumour

The most common location of metastases

Peritoneum 85%Omentum 70%Contralateral ovary 70%Liver 35%Pleura 33%Lung 25%Uterus 20%Vagina 15%Bone 15%

Page 32: Ovarian Tumour

STAGING

The extent of the disease determines the stage and the appropriate form of management.

Page 33: Ovarian Tumour

ⅠGrowth limited to the ovaries ⅠA Growth limited to one ovary; no ascites present containing malignant cells; no tumor on the external surface; capsule intact ⅠB Growth limited to both ovaries; no ascites present containing malignant cells; no tumor on the external surface; capsule intact ⅠC Tumor either stage A or B, but with tumor on the surface of one or botⅠ Ⅰh ovaries; or with ruptured capsule; or with ascites containing malignant cells or with positive peritoneal washings

Ⅱ Growth involving one or both ovaries, with pelvic extension ⅡA Extention and/or metastases to the uterus and/or tubes ⅡB Extention to other pelvic tissues ⅡC Tumor either stage ⅡA or ⅡB, but with tumor on the surface of one or both ovaries; or with capsule(s) ruptured; or with ascites present containing malignant cells or with positive peritoneal washings

Ⅲ Tumor involving one or both ovaries, with peritoneal implants outside the pelvic and/or positive retroperitoneal or inguinal nodes; superficial liver metastasis equals stage Ⅲ. Tumor is limited to the true pelvis, but with histologically proven malignant extention to small bowel or omentum ⅢA Tumor grossly limited to the true pelvis, with negative nodes but with histologcally confirmed microscopic seeding of abdominal peritoneal surfaces ⅢB Tumor involving one or both ovaries, with histologically confirmed inplants of abdominal peritoneal surfaces, none exceeding 2 cm in diameter; nodes are negtive ⅢC Abdominal inplants greater than 2 cm in diameter and/or positive retroperitoneal or inguinal nodes

Ⅳ Growth invoving one or both ovaries with distant metastases. If pleural effusion is present, there must be positive cytologic findings to allot a case to stage Ⅳ; parenchymal liver metastasis equals stage Ⅳ

Table 2. FIGO stages for primary carcinoma of the ovary (1985)

Page 34: Ovarian Tumour

CLINICAL FIDINGS

Page 35: Ovarian Tumour

1. BENIGN OVARIAN TUMORS

These tumors are generally asymptomatic and are found on routine pelvic examination.

On physical examination the most common signs of an ovarian tumor include an adnexal mass (or masses), an abdominal mass.

If the tumors are large enough, they may produce pelvic pain, urinary retention or frequency micturition, rectal discomfort, and bowel obstruction, no ascites.

Page 36: Ovarian Tumour

2. MALIGNANT OVARIAN TUMORS

The evaluation includes a carful history and complete physical examination in addition to a pelvic examination.

Most neoplastic ovarian tumors produce few symptoms. On physical examination the most common signs include

an adnexal mass (or masses), an abdominal mass ascites, or evidence of metastasis.

When interpreting an adnexal mass,it must be remembered that any palpable ovarian mass in a premenarcheal or postmenopausal woman is abnomal.

Page 37: Ovarian Tumour

DIAGNOSIS

Although most ovarian tumors have not special symptoms, they may be diagnosed by patitnts’ age, careful histories and complete physical examination in addition to a pelvic examination.

Page 38: Ovarian Tumour

1. CELLULAR ANALASIS

Ascites or peritoneal washing is of greatest value when the process appears to be early or to be unilateral.

If there is clear extension of malignancy to peritoneal surfaces, if there is omental tumor extension, or if the entire tumor cannot be removed, the peritoneal washing are less value.

Page 39: Ovarian Tumour

2. FINE-NEEDLE PARACENTESIS

Routine paracentesis to obtain samples for cellular analysis is not recommended but may be useful in the diagnosis of advanced or inoperable diseases.

Page 40: Ovarian Tumour

3. OTHER ACCESSORY EXAMINATIONS

Ultrasonography (endovaginal ultrasound) and computed tomography are accurate techniques.

A laparotomy at least for histological purposes is mandatory.

CA125 is the best known marker for ovarian cancer. In young patients, serum βhuman chorionic gonadotrop

hin (β-hCG) , α-fetoprotein (AFP) titres should be determined.

Page 41: Ovarian Tumour

【 DIFFERENTIAL GIAGNOSIS】 1. Benign ovarian tumors and malignant o

varian tumors See table 3

Page 42: Ovarian Tumour

Table 3. Benign ovarian tumors and malignant ovarian tumorsContent Benign Malignant

History Long, growth slowly

Short, growth rapidly

Sign Generally unilateral, active, cystic, smooth, no ascites

Generally bilateral, fixed, solid or semisolid, nodular or lobulated, often with bloody ascites containing malignant cells

General physical condition

Good Cachexia present

Ultrasound Opaque dark area of fluid, with interval band, edge clearly

Opaque dark area of fluid with light beam or sport, edge not clearly

Page 43: Ovarian Tumour

2. DIFFERENTIAL DIAGNOSIS OF BENIGN OVARIAN TUMORS

Page 44: Ovarian Tumour

(1) OVARIAN TUMOR LIKE CONDITION

Follicle cysts and lutein cysts are the most common.

Indeed, in a normally menstruating woman any adnexal mass larger than 5cm should be concidered suspect if it persists for more than 6 weeks.

Page 45: Ovarian Tumour

(2) SALPINGO-OOPHORY CYSTS

These are inflammation cysts and often produce infertility.

Page 46: Ovarian Tumour

(3) LEIOMYOMA

Leiomyomas are generally multiple, linked with uterine, often associated with a menstrual abnormality.

On physical examination, the tumor moves when corpus uteri and cervix move.

Page 47: Ovarian Tumour

(4) UTERINE PREGNANCY

The careful menstrual history, the HCH study, and untrasonography scane may be useful to differentiate the two conditions.

Page 48: Ovarian Tumour

(5) ASCITES

The patient often has history of hepatic disease, or cardiac disease.

When the patient lies down, the shape of her abdomen likes as frog-belly.

Percussion note is tympany in the middle abdomen, dullness in the lateral abdomen. The shifting dullness is positive.

Page 49: Ovarian Tumour

3. DIFFERENTIAL DIAGNOSIS OF MALIGNANT OVARIAN TUMORS

Page 50: Ovarian Tumour

(1) ENDOMETRIOSIS

The lesion generally produces progressive dysmenorrhea, hypermenorrhea, premenstrual irregular vaginal bleeding, and so on.

Ultrasound, laparoscopy are the promising adjuvant examination.

Laparotomy should be performed if ovarian neoplasms cannot be ruled out.

Page 51: Ovarian Tumour

(2) PELVIC INFLAMMATION OF CONNECTIV TISSUE The patient may have history of abortion or

puerperal inflammation. Use of antibiotic may remit symptoms, and make

the mass or masses small or disappear.

Page 52: Ovarian Tumour

(3) TUBERCULOUS PERITONITIS

The lesions often occur in young or infertility women, generally have history of lung tuberculosis, often produce leanness, asthenia, low fever, night sweat, anorexia, infrequent menstruation or amenorrhea.

Ultimately the dignosis of this lesion depends on surgical exploration.

Page 53: Ovarian Tumour

(4) EXTRA-GENERATIVE TRACT TUMORS

Ovarian malignant neoplasms must be differentiated from retroperitoneal masses, rectal cancer or sigmoid cancer.

Untrasound, barium enema, intravenous pyelography may assist in establishing the diagnosis.

Page 54: Ovarian Tumour

(5) METASTATIC OVARIAN TUMORS

The metastatic ovarian neoplasms should be suspect if the adnexal mass or masses were bilateral, median large, kedney shape, active and solid.

The patient has gastrointestinal symptoms, history of gastrointestinal cncer, and breast cancer.

Page 55: Ovarian Tumour

【 COMPLICATION】 Complications include pediculotorsion, capsule r

uptured, inflammation, and malignant transformation. They may produce pelvic pain or abdominal pain, fever, ascities, abdominal mass or masses, and so on.

Page 56: Ovarian Tumour

【 TREATMENT】1. BENIGN TUMORS Operation should be performed while the diag

nosis is established. The extent of surgery depends on the patient’s

age, the patient’s desire of childbearing, and contralateral ovary.

Frozen section should be used at the time of surgery.

Page 57: Ovarian Tumour

2. MALIGNANT TUMORS

(1) SURGERY Surgery is usually performed to establish the type, histol

ogic grading, and stage of the tumor. In certain early or borderline cases, surgery may also be

curative, and in nearly all cases it is a major part of therapy.

At the time of surgery, peritoneal fluid or peritoneal washing should be aspirated for cytologic analysis.

A “second-look” operation is indicated when an inoperable tumor responds so remarkably to adjunctive therapy that surgery becomes feasible.

Page 58: Ovarian Tumour

(2) CHEMOTHERAPY

Since the introduction of cisplatin-based combinations in the 1980s, the outcome of treatment has improved markedly.

Generally, a “pulse therapy regimen” ie, 5 days of therapy per month for 6-8 courses, has been the most commonly accepted program.

Some new drugs (hexamethylmelamine, cisplatin, Carboplatin, adriamycin) are the promising chemotherapeutic agents.

It must be appreciated that these agents are toxic, and the combinations are more noxious than the single agents.(Table 4)

Page 59: Ovarian Tumour

Table 4. Toxicity of chemotherapeutic agents

System Drug

Hepatic toxicity Methotrexate (esprcially chronic low-dose)

Renal toxicity Methotrexate (esprcially high-dose), Cisplatin

Myelosuppressive toxicity Many agents

Peripheral neuropathy Vincristine, Hexamethylmelamine

Ototoxicity Cisplatin

Pulmonary toxicity Bleomycin, Methotrexate, Cyclophosphamide

Cardiac toxicity Doxorubicin (acute or cumulative)

Page 60: Ovarian Tumour

(3) RADIOTHERAPY

Radiation therapy was the prime therapeutic modality for many years, but inability to deliver effective dosages to the upper abdomen without damaging the liver or kidneys limited its usefulness.

Because of the availability of a multitude of chemotherapeutic agents, chemotherapy has recently replaced radiation.

Page 61: Ovarian Tumour

【 PREGNOSIS】 The grade of tumor differentiation and FIGO

substage are most likely the strongest factors predicting for recurrence in early stage.

In the advanced stages, prior to treatment, performance status, FIGO classification, differentiation grade, size of the residual tumor, presence or absence of ascites, and cell type all influence the survival outcome.